(Q45746181)

15 December 2017

title

Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients (English)

1 reference

15 December 2017

1 reference

1 reference

Seta T

1

1 reference

15 December 2017

Yokosuka O

2

1 reference

15 December 2017

Imazeki F

3

1 reference

15 December 2017

Tagawa M

4

1 reference

15 December 2017

Saisho H

5

1 reference

15 December 2017

publication date

1 January 2000

1 reference

15 December 2017

Journal of Medical Virology

published in

1 reference

15 December 2017

volume

60

1 reference

15 December 2017

issue

1

1 reference

15 December 2017

page(s)

8-16

1 reference

15 December 2017

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Natural history of chronic hepatitis B virus infection: new light on an old story.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Mutation rate of the hepadnavirus genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28200001%2960%3A1%3C8%3A%3AAID-JMV2%3E3.0.CO%3B2-U

10.1002/(SICI)1096-9071(200001)60:1<8::AID-JMV2>3.0.CO;2-U

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017